Literature DB >> 7233892

Antimicrobial agent-associated colitis and diarrhea.

W L George.   

Abstract

Although antimicrobial agent-associated colitis has been recognized as a clinicopathologic entity for years, the cause of this disease has been determined only recently. Virtually all cases of pseudomembranous colitis and some cases of antimicrobial agent-associated nonspecific colitis or diarrhea have been shown to be caused by a toxin of Clostridium difficile. Methods for cultivating C difficile from feces and for detecting the toxin have been developed. Oral administration of vancomycin has proved to be effective for the treatment of C difficile-induced colitis, although isolated instances of relapse after treatment have been documented.The discovery of C difficile as a human intestinal pathogen has provided an explanation for some, but not all cases of antimicrobial agent-associated diarrhea. The epidemiology, pathogenesis and means of prevention of C difficile toxin-induced diarrhea remain to be determined.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7233892      PMCID: PMC1272222     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  72 in total

Review 1.  Antimicrobial agent-induced diarrhea--a bacterial disease.

Authors:  W L George; V L Sutter; S M Finegold
Journal:  J Infect Dis       Date:  1977-12       Impact factor: 5.226

2.  Pseudomembranous colitis and co-trimoxazole.

Authors:  A Cameron; M Thomas
Journal:  Br Med J       Date:  1977-05-21

3.  Antibiotic associated pseudomembranous colitis with negative proctosigmoidoscopy examination.

Authors:  F J Tedesco
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

4.  Acute colitis related to penicillin and penicillin derivatives.

Authors:  R B Toffler; E G Pingoud; M I Burrell
Journal:  Lancet       Date:  1978-09-30       Impact factor: 79.321

5.  Penicillin-associated colitis.

Authors:  P de Mulder; T Thien; J F Fennis
Journal:  Lancet       Date:  1978-11-25       Impact factor: 79.321

6.  Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett; F J Tedesco; S Shull; B Lowe; T Chang
Journal:  Gastroenterology       Date:  1980-03       Impact factor: 22.682

7.  Cephalosporin-associated pseudomembranous colitis due to Clostridium difficile.

Authors:  J G Bartlett; S H Willey; T W Chang; B Lowe
Journal:  JAMA       Date:  1979-12-14       Impact factor: 56.272

8.  Cephalosporin-associated pseudomembranous colitis.

Authors:  D F Hutcheon; F D Milligan; J H Yardley; T R Hendrix
Journal:  Am J Dig Dis       Date:  1978-04

9.  Colitis induced by Clostridium difficile.

Authors:  J G Bartlett; T Chang; N S Taylor; A B Onderdonk
Journal:  Rev Infect Dis       Date:  1979 Mar-Apr

10.  Unfavorable effect of atropine-diphenoxylate (Lomotil) therapy in lincomycin-caused diarrhea.

Authors:  E Novak; J G Lee; C E Seckman; J P Phillips; A R DiSanto
Journal:  JAMA       Date:  1976-04-05       Impact factor: 56.272

View more
  5 in total

1.  New Clostridium difficile serotypes in Poland.

Authors:  F Meisel-Mikolajczyk; B Sokól
Journal:  Eur J Epidemiol       Date:  1991-07       Impact factor: 8.082

Review 2.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

3.  In vitro susceptibility of Clostridium difficile isolates to cefotaxime, moxalactam, and cefoperazone.

Authors:  R A Greenfield; T A Kurzynski; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

4.  Nosocomial diarrhoeas in a surgical division hyperendemic for Clostridium difficile: epidemiologic aspects emerging from an analysis of clinical records.

Authors:  P Urbano; S Le Brun
Journal:  Eur J Epidemiol       Date:  1986-12       Impact factor: 8.082

5.  Clostridium difficile and cytotoxin in feces of patients with antimicrobial agent-associated pseudomembranous colitis.

Authors:  W L George; R D Rolfe; G K Harding; R Klein; C W Putnam; S M Finegold
Journal:  Infection       Date:  1982       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.